TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20561886

Group type: EXPERIMENTAL
Intervention: Coping style (anger-in)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Coping style (alexithymia)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Coping style (emotional expression)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Illness knowledge
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Coping styles (anger-in, alexithymia, emotional expression)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Denial-based coping styles
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Avoiding communication of emotions
Number of subjects: 35
Study: 19167910

Group type: EXPERIMENTAL
Intervention: Anesthetic management and extubation in the operating room (early group [EG])
Number of subjects: 100

Group type: COMPARATOR
Intervention: Elective prolonged mechanical ventilation (control group [CG])
Number of subjects: 100
Study: 17204725

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral montelukast
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 83
Study: 14757950

Group type: EXPERIMENTAL
Intervention: Counter-propagation network with variable degree variable step size LMS algorithm
Number of subjects: 0
Study: 10716458

Group type: EXPERIMENTAL
Intervention: Cytochalasin B
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 8957980

Group type: EXPERIMENTAL
Intervention: Normal saline 1000 ml (Group C)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline 500 ml (Group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No fluid load (Group A)
Number of subjects: 34
Study: 1525787

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg once daily
Number of subjects: 56

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 56
Study: 2859042

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31172873

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 7.5 mg of sodium metaphosphate (SMP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control gum without sodium metaphosphate
Number of subjects: 30
Study: 28371155

Group type: EXPERIMENTAL
Intervention: LY2409021 20 mg
Number of subjects: 174
Study: 26659938

Group type: EXPERIMENTAL
Intervention: Juvéderm Volbella with Lidocaine
Number of subjects: 280

Group type: COMPARATOR
Intervention: Restylane‐L
Number of subjects: 280
Study: 22311679

Group type: EXPERIMENTAL
Intervention: Outpatient chemotherapy with S-1 + cisplatin (S-1: 80-120 mg days 1-21; cisplatin: 60 mg/m2 day 8, every 4-5 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Inpatient chemotherapy with intravenous hydration (control group)
Number of subjects: 36
Study: 21658668

Group type: EXPERIMENTAL
Intervention: HPV genotyping using Hybrid Capture II
Number of subjects: 1595

Group type: EXPERIMENTAL
Intervention: Testing for other high-risk HPV types
Number of subjects: 1595
Study: 18473693

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM) with DIABTel telemedicine system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control phase (blind 3-day CGM)
Number of subjects: 10
Study: 17174228

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone
Number of subjects: 949

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study: 12690945

Group type: EXPERIMENTAL
Intervention: Dyadic strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoidant coping and intrusive thinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maladaptive coping
Number of subjects: 0
Study: 10496451

Group type: EXPERIMENTAL
Intervention: Intravenous propafenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 0
Study: 8947984

Group type: EXPERIMENTAL
Intervention: Restrictive formulary (dosage strengths of 25, 50, 100, 125, and 150 micrograms)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Nonrestrictive formulary (dosage strengths of 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 micrograms)
Number of subjects: 241
Study: 1680413

Group type: EXPERIMENTAL
Intervention: PDF with 3.86% glucose (D386)
Number of subjects: 8

Group type: COMPARATOR
Intervention: PDF with 1.36% glucose (D136)
Number of subjects: 8
Study: 7104460

Group type: EXPERIMENTAL
Intervention: 2 x 40 mg oral propranolol hydrochloride tablets
Number of subjects: 18

Group type: COMPARATOR
Intervention: Innovator's product (reference tablet)
Number of subjects: 18
Study: 30916379

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every week (ADAew)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab every other week (ADAew/eow)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (ADAew/pbo)
Number of subjects: 0
Study: 29463950

Group type: EXPERIMENTAL
Intervention: Computer-assisted functional cognitive training (RehaCom) for 10 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Computer-assisted functional cognitive training (RehaCom)
Number of subjects: 58
Study: 27301417

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (OD)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 24526247

Group type: EXPERIMENTAL
Intervention: Acetaminophen/tramadol 325 mg/37.5 mg per capsule, maximum acetaminophen 1,950 mg and tramadol 225 mg per day; treatment duration 2 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, titrated identically to treatment.
Number of subjects: 50
Study: 22399127

Group type: EXPERIMENTAL
Intervention: Spring-loaded syringe (n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Loss-of-resistance syringe (n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hanging drop technique (n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 19460715

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with trastuzumab
Number of subjects: 3

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 3
Study: 17627399

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment regimens
Number of subjects: 5017
Study: 15867582

Group type: EXPERIMENTAL
Intervention: Growth Hormone (0.05 mg/kg per day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 12062539

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (1000 mg bolus given 1 day before angioplasty)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-dose aspirin (100 mg/day only)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no aspirin intervention)
Number of subjects: 51
Study: 9828247

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (5 mg each, up to 15 doses)
Number of subjects: 3327

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (1 mg each, up to 15 doses)
Number of subjects: 3327
Study: 10220206

Group type: EXPERIMENTAL
Intervention: Lispro + NPH (5 min before breakfast and lunch, lispro before dinner, NPH at bedtime)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lispro + NPH
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soluble insulin + NPH (20‐30 min before each meal and NPH at bedtime)
Number of subjects: 25
Study: 1703916

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by definitive radiation therapy (RT) - 70 Gy to involved areas and 50 Gy to uninvolved neck at 2 Gy/fraction, five fractions per week.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Alternating chemotherapy and radiation therapy (RT) - 60 Gy to involved areas and 50 Gy to uninvolved neck in three courses of 20 Gy each, 2 Gy/fraction, ten fractions/2 weeks alternated with four courses of chemotherapy.
Number of subjects: 116
Study: 6305387

Group type: EXPERIMENTAL
Intervention: benoxaprofen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 30557623

Group type: EXPERIMENTAL
Intervention: 15 weeks of programmed vigorous-intensity exercise
Number of subjects: 150

Group type: COMPARATOR
Intervention: 15 weeks of programmed low-intensity exercise
Number of subjects: 150
Study: 29304531

Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplement (SiS nitrate gel)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clopidogrel therapy
Number of subjects: 20
Study: 25261789

Group type: EXPERIMENTAL
Intervention: Nicotine content instructions (e‐cigarette contained nicotine)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nicotine content instructions (e‐cigarette was nicotine-free)
Number of subjects: 21
Study: 23290154

Group type: EXPERIMENTAL
Intervention: Theophylline plus SFC (200 mg theophylline plus 50/250 μg SFC)
Number of subjects: 325

Group type: COMPARATOR
Intervention: SFC plus placebo (placebo tablet plus 50/250 μg SFC)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Theophylline plus SFC
Number of subjects: 325

Group type: COMPARATOR
Intervention: SFC plus placebo
Number of subjects: 325
Study: 21906278

Group type: EXPERIMENTAL
Intervention: Clinician-directed, Internet-delivered intervention for improving care
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Structured recruitment with physician recruiters and dedicated IRB manager
Number of subjects: 957
Study: 18226936

Group type: EXPERIMENTAL
Intervention: Exercise and advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice alone
Number of subjects: 0
Study: 16816224

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554
Study: 12535199

Group type: EXPERIMENTAL
Intervention: Commercial sunscreen (SPF 15)
Number of subjects: 119
Study: 10674611

Group type: EXPERIMENTAL
Intervention: Stapled closure
Number of subjects: 141

Group type: COMPARATOR
Intervention: Sutured closure
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study: 8790022

Group type: EXPERIMENTAL
Intervention: Reteplase (10 plus 10 megaunits double bolus)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Alteplase (front-loaded)
Number of subjects: 324
Study: 1297907

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6494811

Group type: EXPERIMENTAL
Intervention: Netilmicin + Tinidazole (N + T)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Netilmicin + Clindamycin (N + C)
Number of subjects: 41
Study: 31605923

Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 320/18/9.6 μg
Number of subjects: 8572

Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 160/18/9.6 μg
Number of subjects: 8572

Group type: COMPARATOR
Intervention: Glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 μg
Number of subjects: 8572

Group type: COMPARATOR
Intervention: Budesonide/formoterol fumarate (BFF) MDI 320/9.6 μg
Number of subjects: 8572
Study: 29284320

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir
Number of subjects: 123

Group type: COMPARATOR
Intervention: Oral oseltamivir
Number of subjects: 123

Group type: COMPARATOR
Intervention: Inhaled zanamivir
Number of subjects: 123

Group type: COMPARATOR
Intervention: Inhaled laninamivir
Number of subjects: 123
Study: 26655020

Group type: EXPERIMENTAL
Intervention: Hydrogenated vegetable oils (HVOs) consumption
Number of subjects: 1582

Group type: EXPERIMENTAL
Intervention: Butter consumption
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Non-hydrogenated vegetable oils (non-HVOs) consumption
Number of subjects: 1582

Group type: COMPARATOR
Intervention: Non-consumption of butter
Number of subjects: 1582
Study: 23877621

Group type: EXPERIMENTAL
Intervention: Warfarin maintenance dosing algorithm
Number of subjects: 537

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 537
Study: 22822010

Group type: EXPERIMENTAL
Intervention: Buttonhole needling
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard needling
Number of subjects: 140
Study: 20042648

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting regimen
Number of subjects: 24
Study: 17108011

Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic intraocular lens (IOL)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hydrophobic acrylic intraocular lens (IOL)
Number of subjects: 53
Study: 15860711

Group type: EXPERIMENTAL
Intervention: Strength exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: High intensity exercise (80% of maximum exercise capacity)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Interval exercise
Number of subjects: 15
Study: 12004217

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 74

Group type: COMPARATOR
Intervention: Coloanal anastomosis
Number of subjects: 74
Study: 9547085

Group type: EXPERIMENTAL
Intervention: Visual delay of 0% of cycle duration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Visual delay of 100% of cycle duration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Visual delay of about 50% of cycle duration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Visual delays up to 50% of target cycle duration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Visual delays larger than 50% of target cycle duration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Different visual delays ranging from 0 to 120% of cycle duration
Number of subjects: 5
Study: 9894360

Group type: EXPERIMENTAL
Intervention: Retinyl propionate cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 80
Study: 2653717

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) 200 mg/kg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ampicillin (AMP) and chloramphenicol succinate (CAPS)
Number of subjects: 50
Study: 814180

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 20
Study: 30819077

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 55
Study: 27324833

Group type: COMPARATOR
Intervention: Device-only feedback (DFB)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Verbal feedback from a qualified dental instructor (IFB)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Combination of instructor and device feedback (IDFB)
Number of subjects: 63
Study: 25938855

Group type: EXPERIMENTAL
Intervention: MIRRORS (Mindfulness Intervention for Rehabilitation and Recovery in Schizophrenia)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intensive Support
Number of subjects: 34
Study: 23478860

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Number of subjects: 55779

Group type: EXPERIMENTAL
Intervention: Performance Feedback
Number of subjects: 55779

Group type: EXPERIMENTAL
Intervention: Combined CDS and Performance Feedback
Number of subjects: 55779

Group type: COMPARATOR
Intervention: Non-CDS visits
Number of subjects: 55779
Study: 21824799

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of conjugated equine estrogens
Number of subjects: 23

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 23
Study: 19309184

Group type: EXPERIMENTAL
Intervention: Alcohol Behavioral Couple Therapy (ABCT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Alcohol Behavioral Individual Therapy (ABIT)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: ABCT
Number of subjects: 102
Study: 16886978

Group type: EXPERIMENTAL
Intervention: Rufinamide 200 mg/day
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Rufinamide 400 mg/day
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Rufinamide 800 mg/day
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Rufinamide 1600 mg/day
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 15260911

Group type: EXPERIMENTAL
Intervention: rilmenidine 3 mg once daily
Number of subjects: 15
Study: 11726259

Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Stairstepper
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All modes of exercise
Number of subjects: 18
Study: 9159031

Group type: COMPARATOR
Intervention: Ulcerative colitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crohn's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison between Crohn's disease and ulcerative colitis
Number of subjects: 0
Study: 7895460

Group type: EXPERIMENTAL
Intervention: Metformin and Glibenclamide (MGL)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Monotherapy (Metformin or Glibenclamide)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Combination therapy (Metformin and Glibenclamide)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 165
Study: 2441013

Group type: EXPERIMENTAL
Intervention: Monthly group sessions with videotapes for diabetic persons with low literacy skills
Number of subjects: 120

Group type: COMPARATOR
Intervention: Monthly group sessions without videotapes
Number of subjects: 120

Group type: COMPARATOR
Intervention: No monthly sessions
Number of subjects: 120
Study: 30144017

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 129
Study: 27245741

Group type: EXPERIMENTAL
Intervention: PPROM for ≥3 weeks
Number of subjects: 1305

Group type: COMPARATOR
Intervention: PPROM for <3 weeks
Number of subjects: 1305
Study: 25654961

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD; Emdogain)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both EMD and PRF
Number of subjects: 30
Study: 22909093

Group type: EXPERIMENTAL
Intervention: Information provided by prescribers
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lack of information or support
Number of subjects: 12
Study: 20132153

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 52
Study: 19077067

Group type: EXPERIMENTAL
Intervention: Conservative management with medium chain triglyceride-enriched diet or total parenteral nutrition in combination with adequate drainage of pleural fluid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Somatostatin or octreotide therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm for therapeutic approach to management
Number of subjects: 0
Study: 15673645

Group type: EXPERIMENTAL
Intervention: Pamphlet intervention
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pamphlet plus video intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study: 12093420

Group type: EXPERIMENTAL
Intervention: Preventive health visits
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Physician's recommendation for FSIG or FOBT cards
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Insurance status
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Type of insurance
Number of subjects: 1002
Study: 10528370

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein 2 with Type I collagen carrier
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein 2 with polylactic acid carrier
Number of subjects: 6

Group type: COMPARATOR
Intervention: Collagen carrier alone (no recombinant human bone morphogenetic protein 2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Autogenous rib graft alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Recombinant human bone morphogenetic protein 2 treatment groups
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Collagen carrier
Number of subjects: 6
Study: 7727671

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 28
Study: 2139285

Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (YDV) 20 micrograms, administered according to a 0, 1, 6 month schedule.
Number of subjects: 275
Study: 507790

Group type: EXPERIMENTAL
Intervention: Gentamicin or Tobramycin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ideal body weight for AMG dosage calculation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AMG-induced nephrotoxicity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Peak AMG serum concentrations
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Serum inhibitory levels of greater than or equal to 1:8
Number of subjects: 120

Group type: COMPARATOR
Intervention: Mortality between gentamicin and tobramycin
Number of subjects: 120
Study: 31830753

Group type: EXPERIMENTAL
Intervention: Dual-site rTMS treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 28711109

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Short-Term Psychodynamic Supportive Psychotherapy (SPSP)
Number of subjects: 282
Study: 25015237

Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men (CBIM) program
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study: 23578592

Group type: EXPERIMENTAL
Intervention: CR Equipements SACH foot
Number of subjects: 15

Group type: COMPARATOR
Intervention: SACH foot
Number of subjects: 15
Study: 21323524

Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg on day +1
Number of subjects: 40

Group type: COMPARATOR
Intervention: filgrastim (daily starting at median day +7)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: pegfilgrastim and filgrastim
Number of subjects: 40
Study: 19369086

Group type: EXPERIMENTAL
Intervention: Lisinopril (postoperatively)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No angiotensin converting enzyme inhibitor (control group)
Number of subjects: 21